Cytosage is targeting neurodegeneration, traumatic brain injury and acute immune-inflammatory disorders for treatment with allogeneic cell therapy

Unmet Need in CNS-related immune-inflammatory components

CNS and peripheral neurodegeneration, traumatic brain injury and stroke exhibit aspects of immune system dysfunction. ALS, for example, exhibits aspects of both innate and cellular immunity. Likewise, compiled clinical data demonstrate that patients who survive the first 48 hours after stroke onset are more likely to die from immune related dysfunction. In traumatic brain injury, secondary co-morbidity also has immune and inflammatory components , such as acute respiratory distress syndrome.

Following the onset of acute inflammatory conditions in patients, initiated by external severe traumatic injuries or internal pathological conditions such as acute stroke, clinical data suggests approximately 50% of these patients progress to more severe secondary immune mediated pathology such as ARDS, sepsis, acute kidney injury, acute lung injury, etc. Identifying which patients are likely to progress to these pathological conditions earlier would provide improved treatment options and patient outcomes.

Cytosage will use its translational and clinical development experience in cell therapy to stratify patients in these conditions for targeted treatment with allogenic regulatory T cells.